Operating Expenses Summary of Adimmune Corporation

Adimmune Corporation's latest annual operating expenses in 2023 was 1.13 Billion TWD , up 43.05% from previous year.
Adimmune Corporation's latest quarterly operating expenses in 2024 Q2 was 246.62 Million TWD , up 122.26% from previous quarter.
Adimmune Corporation reported a annual operating expenses of 792.52 Million TWD in annual operating expenses 2022, up 18.12% from previous year.
Adimmune Corporation reported a annual operating expenses of 670.95 Million TWD in annual operating expenses 2021, up 3.4% from previous year.
Adimmune Corporation reported a quarterly operating expenses of 246.62 Million TWD for 2024 Q2, up 122.26% from previous quarter.
Adimmune Corporation reported a quarterly operating expenses of 465.05 Million TWD for 2023 Q4, up 160.97% from previous quarter.

Annual Operating Expenses Chart of Adimmune Corporation (2023 - 2009)

Historical Annual Operating Expenses of Adimmune Corporation (2023 - 2009)

Year	Operating Expenses	Operating Expenses Growth
2023	1.13 Billion TWD	43.05%
2022	792.52 Million TWD	18.12%
2021	670.95 Million TWD	3.4%
2020	648.87 Million TWD	39.07%
2019	466.56 Million TWD	10.51%
2018	422.18 Million TWD	-4.91%
2017	443.98 Million TWD	10.11%
2016	403.22 Million TWD	-9.82%
2015	447.11 Million TWD	1.06%
2014	442.41 Million TWD	10.86%
2013	399.06 Million TWD	34.77%
2012	296.11 Million TWD	-15.82%
2011	351.74 Million TWD	11.46%
2010	315.58 Million TWD	10.91%
2009	284.53 Million TWD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	115.62 Million TWD	-75.14%
2024 Q2	246.62 Million TWD	122.26%
2023 Q4	465.05 Million TWD	160.97%
2023 FY	1.13 Billion TWD	43.05%
2023 Q3	178.2 Million TWD	9.07%
2023 Q1	199.68 Million TWD	-3.03%
2023 Q2	163.38 Million TWD	-18.18%
2022 FY	792.52 Million TWD	18.12%
2022 Q1	139.32 Million TWD	-12.37%
2022 Q2	245.19 Million TWD	75.98%
2022 Q4	205.92 Million TWD	1.91%
2022 Q3	202.07 Million TWD	-17.59%
2021 FY	670.95 Million TWD	3.4%
2021 Q4	158.99 Million TWD	17.97%
2021 Q1	195.75 Million TWD	-32.96%
2021 Q2	181.42 Million TWD	-7.32%
2021 Q3	134.77 Million TWD	-25.71%
2020 Q3	141.76 Million TWD	17.56%
2020 Q2	120.59 Million TWD	27.56%
2020 Q1	94.53 Million TWD	-28.15%
2020 Q4	291.98 Million TWD	105.97%
2020 FY	648.87 Million TWD	39.07%
2019 Q3	105.26 Million TWD	-21.95%
2019 FY	466.56 Million TWD	10.51%
2019 Q1	94.85 Million TWD	-17.13%
2019 Q2	134.87 Million TWD	42.19%
2019 Q4	131.57 Million TWD	24.99%
2018 Q3	120.59 Million TWD	25.45%
2018 FY	422.18 Million TWD	-4.91%
2018 Q4	114.45 Million TWD	-5.09%
2018 Q2	96.13 Million TWD	5.64%
2018 Q1	90.99 Million TWD	-13.83%
2017 Q2	151.41 Million TWD	52.79%
2017 FY	443.98 Million TWD	10.11%
2017 Q3	87.86 Million TWD	-41.97%
2017 Q1	99.1 Million TWD	-12.16%
2017 Q4	105.6 Million TWD	20.18%
2016 Q3	116.67 Million TWD	7.09%
2016 FY	403.22 Million TWD	-9.82%
2016 Q1	64.77 Million TWD	-55.55%
2016 Q2	108.95 Million TWD	68.21%
2016 Q4	112.82 Million TWD	-3.3%
2015 Q4	145.72 Million TWD	31.32%
2015 FY	447.11 Million TWD	1.06%
2015 Q3	110.96 Million TWD	11.21%
2015 Q1	90.65 Million TWD	-37.58%
2015 Q2	99.77 Million TWD	10.06%
2014 Q3	89.54 Million TWD	-22.12%
2014 Q4	145.24 Million TWD	62.2%
2014 Q1	92.63 Million TWD	-48.24%
2014 FY	442.41 Million TWD	10.86%
2014 Q2	114.98 Million TWD	24.12%
2013 Q3	102.89 Million TWD	62.87%
2013 Q1	54 Million TWD	-45.41%
2013 FY	399.06 Million TWD	34.77%
2013 Q4	178.98 Million TWD	73.95%
2013 Q2	63.17 Million TWD	16.98%
2012 Q2	76.67 Million TWD	43.03%
2012 Q4	98.93 Million TWD	49.55%
2012 Q3	66.15 Million TWD	-13.73%
2012 Q1	53.61 Million TWD	-51.45%
2012 FY	296.11 Million TWD	-15.82%
2011 Q3	94.64 Million TWD	6.72%
2011 FY	351.74 Million TWD	11.46%
2011 Q4	110.41 Million TWD	16.66%
2011 Q2	88.69 Million TWD	52.93%
2011 Q1	57.99 Million TWD	-54.59%
2010 Q3	48.09 Million TWD	0.0%
2010 FY	315.58 Million TWD	10.91%
2010 Q4	127.7 Million TWD	165.54%
2009 FY	284.53 Million TWD	0.0%

Peer Operating Expenses Comparison of Adimmune Corporation

Name	Operating Expenses	Operating Expenses Difference
Apex Biotechnology Corp.	389.4 Million TWD	-191.136%
Sinphar Pharmaceutical Co.,Ltd.	807.86 Million TWD	-40.33%
Panion & Bf Biotech Inc.	817.56 Million TWD	-38.665%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	437.58 Million TWD	-159.078%
GenMont Biotech Incorporation	204.2 Million TWD	-455.171%
Abnova (Taiwan) Corporation	126.72 Million TWD	-794.628%
Tanvex BioPharma, Inc.	2.16 Billion TWD	47.526%
Polaris Group	-3.06 Million TWD	37087.993%
Energenesis Biomedical CO.,LTD.	267.06 Million TWD	-324.498%
UnicoCell Biomed Co., Ltd.	17.89 Million TWD	-6234.481%
PELL Bio-Med Technology Co. Ltd.	385.1 Million TWD	-194.382%

Global Stocks Search

Adimmune Corporation (4142.TW)

Operating Expenses Summary of Adimmune Corporation

Annual Operating Expenses Chart of Adimmune Corporation (2023 - 2009)

Historical Annual Operating Expenses of Adimmune Corporation (2023 - 2009)

Peer Operating Expenses Comparison of Adimmune Corporation